<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945138</url>
  </required_header>
  <id_info>
    <org_study_id>CLTPIAT2013</org_study_id>
    <secondary_id>21856</secondary_id>
    <nct_id>NCT01945138</nct_id>
  </id_info>
  <brief_title>Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation</brief_title>
  <official_title>Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota, MN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of closed loop insulin pump
      therapy to control blood sugar following total pancreatectomy and islet auto-transplantation
      (TPIAT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES AND HYPOTHESES The main objective of this study is to determine if a closed loop
      insulin system can successfully achieve tighter blood sugar control than the current multiple
      daily injection regimen. The investigators hypothesize that the average blood glucose will be
      lower in the closed loop group than the control group, there will be less glucose variability
      in the closed loop group than the control group, and there will be less total time spent in
      hyperglycemia and hypoglycemia in the closed loop group than in the control group. The
      investigators also will investigate insulin requirements and islet function in the first 6
      months post-transplant in the closed loop group The investigators hypothesize that the
      insulin requirements will be lower and the C-peptide levels higher in the closed loop group
      than in the control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Period: Average Serum BG</measure>
    <time_frame>3 days of investigation period</time_frame>
    <description>Mean blood glucose value: a single report of the average of the analytical blood glucose values will be computed and compared between the pump and control groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study Period: Serum BG Standard Deviation</measure>
    <time_frame>3 days of investigation period</time_frame>
    <description>Measure of glycemic variability. This is the standard deviation in all serum BG values for each individual patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Period: Continuous Glucose Monitor (CGM) BG Average</measure>
    <time_frame>continuously over the 72 hour investigational period</time_frame>
    <description>Continuous glucose monitoring sensor data: The CGM's in the pump and control groups will collect glucose readings continuously over a 72 hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: Continuous Glucose Monitor Standard Deviation of BG</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
    <description>measure of glycemic variability by CGM. This is the standard deviation within each patient for all CGM glucose readings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: Percent Time BG in Range 70-140 mg/dL</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
    <description>Additional measure of glycemic variability, as reflected by CGM measures, % time in the range of 70-140 on CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: CGM Area Under the Curve (AUC) With Glucose &lt; 70 mg/dL</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
    <description>Calculated as the area under the curve on the CGM tracing that the glucose is under 70 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: % of Time CGM BG &lt;70 mg/dL</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: CGM AUC With Glucose&gt; 140 mg/dL</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: % of Time CGM BG &gt; 140 mg/dL</measure>
    <time_frame>continuous over the 72 hour investigation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: Morning C-peptide</measure>
    <time_frame>Average of 3 day study period</time_frame>
    <description>A single C-peptide measurement collected daily x 3 days, collected at random (meaning not in a fasting state) each morning. Expressed as average for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Period: Daily Insulin Needs</measure>
    <time_frame>Average of 3 day study period</time_frame>
    <description>Calculated as total daily dose of insulin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 Follow-Up: Average Serum BG</measure>
    <time_frame>Day 14 Follow-Up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 14 Follow-Up: C-Peptide</measure>
    <time_frame>Day 14 Follow-Up:</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 Follow-Up: Average Serum BG</measure>
    <time_frame>Day 28 Follow-Up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 28 Follow-Up: C-Peptide</measure>
    <time_frame>Day 28 Follow-Up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Closed Loop Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed Loop Insulin</intervention_name>
    <description>The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
    <arm_group_label>Closed Loop Insulin</arm_group_label>
    <other_name>Medtronic ePID 2.0 system</other_name>
    <other_name>Medtronic Paradigm REAL-Time Insulin Pump (MMT-722)</other_name>
    <other_name>Enlite Glucose Sensor (MMT-7008X)</other_name>
    <other_name>MiniLink REAL-Time Transmitter (MMT-7703XNA)</other_name>
    <other_name>ComLink Device (MMT-7304)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing total pancreatectomy and islet auto-transplantation.

          -  Patients ages 21 to 64 years old

        Exclusion Criteria:

          -  Preexisting diabetes

          -  Use of acetaminophen during study period, which interferes with CGM sensor function

          -  Any medical condition requiring corticosteroids

          -  Severe Psychiatric disease or developmental delays, that might interfere with the
             ability to provide informed consent

          -  Any other medical condition which in the opinion of the investigators impairs the
             person's ability to safely participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melena Bellin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <results_first_submitted>June 15, 2015</results_first_submitted>
  <results_first_submitted_qc>December 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2016</results_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Pancreatectomy</keyword>
  <keyword>Islet Auto-Transplantation</keyword>
  <keyword>Closed Loop Insulin Pump</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
        </group>
        <group group_id="P2">
          <title>Closed Loop Insulin</title>
          <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
        </group>
        <group group_id="B2">
          <title>Closed Loop Insulin</title>
          <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="13.3"/>
                    <measurement group_id="B2" value="38.6" spread="9.4"/>
                    <measurement group_id="B3" value="35.9" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at Transplant</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.7" spread="23.7"/>
                    <measurement group_id="B2" value="66.1" spread="10.3"/>
                    <measurement group_id="B3" value="71.4" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI) at Transplant</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="5.7"/>
                    <measurement group_id="B2" value="25.3" spread="4.5"/>
                    <measurement group_id="B3" value="25.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hemoglobin A1c (A1c)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="0.5"/>
                    <measurement group_id="B2" value="5.1" spread="0.2"/>
                    <measurement group_id="B3" value="5.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Blood Glucose (BG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95" spread="13"/>
                    <measurement group_id="B2" value="89" spread="6"/>
                    <measurement group_id="B3" value="92" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting C-Peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95" spread="13"/>
                    <measurement group_id="B2" value="89" spread="6"/>
                    <measurement group_id="B3" value="92" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Mixed Meal Tolerance Test (MMTT) C-peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="4.4"/>
                    <measurement group_id="B2" value="6.4" spread="2.2"/>
                    <measurement group_id="B3" value="6.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Islet Yield</title>
          <units>IEq/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4245" spread="2174"/>
                    <measurement group_id="B2" value="6619" spread="3357"/>
                    <measurement group_id="B3" value="5432" spread="2983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days on drip</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" spread="1.1"/>
                    <measurement group_id="B2" value="5.1" spread="1.1"/>
                    <measurement group_id="B3" value="6.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology of Chronic Pancreatitis (CP)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Identified Genetic Mutation (PRSS1, SPINK1, CFTR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mechanical Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Idiopathic Pancreatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study Period: Average Serum BG</title>
        <description>Mean blood glucose value: a single report of the average of the analytical blood glucose values will be computed and compared between the pump and control groups.</description>
        <time_frame>3 days of investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Average Serum BG</title>
          <description>Mean blood glucose value: a single report of the average of the analytical blood glucose values will be computed and compared between the pump and control groups.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="13"/>
                    <measurement group_id="O2" value="111" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Study Period: Serum BG Standard Deviation</title>
        <description>Measure of glycemic variability. This is the standard deviation in all serum BG values for each individual patient.</description>
        <time_frame>3 days of investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Serum BG Standard Deviation</title>
          <description>Measure of glycemic variability. This is the standard deviation in all serum BG values for each individual patient.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="10.2"/>
                    <measurement group_id="O2" value="14.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.115</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: Continuous Glucose Monitor (CGM) BG Average</title>
        <description>Continuous glucose monitoring sensor data: The CGM's in the pump and control groups will collect glucose readings continuously over a 72 hour period</description>
        <time_frame>continuously over the 72 hour investigational period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Continuous Glucose Monitor (CGM) BG Average</title>
          <description>Continuous glucose monitoring sensor data: The CGM's in the pump and control groups will collect glucose readings continuously over a 72 hour period</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" spread="20"/>
                    <measurement group_id="O2" value="114" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.193</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: Continuous Glucose Monitor Standard Deviation of BG</title>
        <description>measure of glycemic variability by CGM. This is the standard deviation within each patient for all CGM glucose readings.</description>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Continuous Glucose Monitor Standard Deviation of BG</title>
          <description>measure of glycemic variability by CGM. This is the standard deviation within each patient for all CGM glucose readings.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="10.3"/>
                    <measurement group_id="O2" value="20.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.848</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: Percent Time BG in Range 70-140 mg/dL</title>
        <description>Additional measure of glycemic variability, as reflected by CGM measures, % time in the range of 70-140 on CGM</description>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Percent Time BG in Range 70-140 mg/dL</title>
          <description>Additional measure of glycemic variability, as reflected by CGM measures, % time in the range of 70-140 on CGM</description>
          <units>% of time</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="48.0" upper_limit="93.1"/>
                    <measurement group_id="O2" value="89.2" lower_limit="83.5" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: CGM Area Under the Curve (AUC) With Glucose &lt; 70 mg/dL</title>
        <description>Calculated as the area under the curve on the CGM tracing that the glucose is under 70 mg/dL.</description>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: CGM Area Under the Curve (AUC) With Glucose &lt; 70 mg/dL</title>
          <description>Calculated as the area under the curve on the CGM tracing that the glucose is under 70 mg/dL.</description>
          <units>min*mg/dL/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1615" spread="4267"/>
                    <measurement group_id="O2" value="146" spread="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: % of Time CGM BG &lt;70 mg/dL</title>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: % of Time CGM BG &lt;70 mg/dL</title>
          <units>% of time</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="-6.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-0.3" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.461</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: CGM AUC With Glucose&gt; 140 mg/dL</title>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: CGM AUC With Glucose&gt; 140 mg/dL</title>
          <units>min*mg/dL/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7860" spread="11444"/>
                    <measurement group_id="O2" value="2025" spread="1177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.205</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: % of Time CGM BG &gt; 140 mg/dL</title>
        <time_frame>continuous over the 72 hour investigation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: % of Time CGM BG &gt; 140 mg/dL</title>
          <units>% of time</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="1.5" upper_limit="46.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="4.9" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: Morning C-peptide</title>
        <description>A single C-peptide measurement collected daily x 3 days, collected at random (meaning not in a fasting state) each morning. Expressed as average for each patient.</description>
        <time_frame>Average of 3 day study period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Morning C-peptide</title>
          <description>A single C-peptide measurement collected daily x 3 days, collected at random (meaning not in a fasting state) each morning. Expressed as average for each patient.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.443</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Period: Daily Insulin Needs</title>
        <description>Calculated as total daily dose of insulin.</description>
        <time_frame>Average of 3 day study period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Study Period: Daily Insulin Needs</title>
          <description>Calculated as total daily dose of insulin.</description>
          <units>U/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.31"/>
                    <measurement group_id="O2" value="0.26" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 14 Follow-Up: Average Serum BG</title>
        <time_frame>Day 14 Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Day 14 Follow-Up: Average Serum BG</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="81"/>
                    <measurement group_id="O2" value="106" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.401</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 14 Follow-Up: C-Peptide</title>
        <time_frame>Day 14 Follow-Up:</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Day 14 Follow-Up: C-Peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.9"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 28 Follow-Up: Average Serum BG</title>
        <time_frame>Day 28 Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Day 28 Follow-Up: Average Serum BG</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" spread="29"/>
                    <measurement group_id="O2" value="100" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.325</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 28 Follow-Up: C-Peptide</title>
        <time_frame>Day 28 Follow-Up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop Insulin</title>
            <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
          </group>
        </group_list>
        <measure>
          <title>Day 28 Follow-Up: C-Peptide</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.2"/>
                    <measurement group_id="O2" value="1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.311</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.</description>
        </group>
        <group group_id="E2">
          <title>Closed Loop Insulin</title>
          <description>Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
Closed Loop Insulin: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Hypoglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Melena Bellin</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-5409</phone>
      <email>bell0130@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

